Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Items 201–300 of 1,002
A concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 141
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
Gross, D., Graff‐Dubois, S., Opolon, P., Cornet, S., Alves, P. M. S., Griscelli, A. B., Faure, O., Guillaume, P., Firat, H., Chouaïb, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19418 · Cited by 139
“Cellular or gene therapy protocols based on dendritic cells (11), exosomes (12), heat shock proteins (13), or recombinant virus (14) have also been successful in the induction of protective immunity in mice.”
Coelho, A. C., & García‐Díez, J. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00056 · Cited by 139
“Since they are highly infectious and may infect and propagate themselves in human cells, they may be considered as an important biohazard to the laboratory staff (Thomas et al., 2003; Anson, 2004).”
BackgroundmicroRNAs as cancer therapeutics: A step closer to clinical application
Ivković, T. C., Voss, G., Cornellà, H., & Ceder, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.007 · Cited by 137
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
“Common concerns are safety, viral tropism (target specificity), immunogenicity, ability to elicit strong and stable transgene expression, and the possibility to produce the vector at high titers [2,3].”
BackgroundLeung, D. C., Dong, K. B., Maksakova, I. A., Goyal, P., Appanah, R., Lee, S., Tachibana, M., Shinkai, Y., Lehnertz, B., Mager, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014660108 · Cited by 125
“MLV-based retroviral vectors similar to those used in this study have been used extensively for gene transfer studies and to deliver genes for therapeutic purposes (43).”
MethodIn vivo bioluminescence for tracking cell fate and function
de Almeida, P. E., van Rappard, J. R. M., & Wu, J. C. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00337.2011 · Cited by 136
Acoustofluidic sonoporation for gene delivery to human hematopoietic stem and progenitor cells
Belling, J. N., Heidenreich, L. K., Tian, Z., Mendoza, A. M., Chiou, T., Gong, Y., Chen, N., Young, T. D., Wattanatorn, N., Park, J. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917125117 · Cited by 136
“Such indiscriminate chromosomal integration can lead to inefficient gene transfer and offtarget effects, such as insertional mutations (3).”
BackgroundMicrofluidic and Nanofluidic Intracellular Delivery
Hur, J., & Chung, A. J. (2021) · Advanced Science · doi:10.1002/advs.202004595 · Cited by 135
Current investigations into carbon nanotubes for biomedical application
Li, X., Fan, Y., & Watari, F. (2010) · Biomedical Materials · doi:10.1088/1748-6041/5/2/022001 · Cited by 134
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy
Wang, X., Qiu, Y., Wang, M., Zhang, C.-H., Zhang, T., Zhou, H., Zhao, W., Zhao, W., Xia, G., & Shao, R. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s274289 · Cited by 135
“Although virus-based carriers, like the lentiviral system, are used with high transfection efficiency, security of viral vectors is not guaranteed due to strong immunogenicity and mutagenesis caused by random integration of viral DNA.121 In contrast, NMs, as non-viral carriers with low immunogenicity and safety profil…”
BackgroundZhao, H., Li, T., Yao, C., Gu, Z., Liu, C., Li, J., & Yang, D. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21006 · Cited by 134
Blackiston, D., Adams, D. S., Lemire, J. M., Lobikin, M., & Levin, M. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.005561 · Cited by 130
“…bioelectrical controls of cell behavior for regenerative medicine or oncology, it is essential to develop techniques that do not rely on the introduction of transgenes because of the numerous problems attendant with gene therapy in human patients (Pfeifer and Verma, 2001; Thomas et al., 2003).”
BackgroundMeacham, J. M., Durvasula, K., Degertekin, F. L., & Fedorov, A. G. (2013) · SLAS TECHNOLOGY · doi:10.1177/2211068213494388 · Cited by 134
“An electrophoretic effect has long been implicated as the driver of the negatively charged DNA molecules across the permeabilized membrane and toward the cell interior.65,66 Further, experimental observations indicate that DNA enters only the more destabilized side of the cell facing the cathode.67 Thus, the surface a…”
BackgroundPrecise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases
Tou, C. J., Orr, B. C., & Kleinstiver, B. P. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01574-x · Cited by 134
Effects of Base Polymer Hydrophobicity and End-Group Modification on Polymeric Gene Delivery
Sunshine, J. C., Akanda, M. I., Li, D., Kozielski, K., & Green, J. J. (2011) · Biomacromolecules · doi:10.1021/bm200807s · Cited by 133
Nanomaterials for in situ cell delivery and tissue regeneration☆
Wan, A. C. A., & Ying, J. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.02.002 · Cited by 133
Maintaining the silence: reflections on long-term RNAi
Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.008 · Cited by 135
“Although much progress has been made in the development of viral gene therapy vectors, there are still important safety concerns that remain troublesome [170] .”
BackgroundA Collaborative Assembly Strategy for Tumor-Targeted siRNA Delivery
Sun, Q., Kang, Z., Xue, L., Shang, Y., Su, Z., Sun, H., Ping, Q., Mo, R., & Zhang, C. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b01435 · Cited by 125
Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics
Ewert, K. K., Scodeller, P., Simón‐Gracia, L., Steffes, V. M., Wonder, E. A., Teesalu, T., & Safinya, C. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091365 · Cited by 132
Xie, Y., Kim, N. H., Nadithe, V., Schalk, D. L., Thakur, A. B., Kılıç, A., Lum, L. G., Bassett, D. J. P., & Merkel, O. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.029 · Cited by 130
“However, the fabrication of viral vectors is time and cost consuming, and their potential safety issues limit their clinical application [17].”
BackgroundFunctionalized nanogels carrying an anticancer microRNA for glioblastoma therapy
Shatsberg, Z., Zhang, X., Ofek, P., Malhotra, S., Krivitsky, A., Scomparin, A., Tiram, G., Calderón, M., Haag, R., & Satchi‐Fainaro, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.029 · Cited by 130
“Viral vectors are efficient delivery agents but may display toxicity and immunogenicity when introduced in vivo [15].”
BackgroundSioud, M. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.11.006 · Cited by 130
Bioreducible Hyperbranched Poly(amido amine)s for Gene Delivery
Chen, J., Wu, C., & Oupický, D. (2009) · Biomacromolecules · doi:10.1021/bm900724c · Cited by 128
A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo
Lehto, T., Simonson, O. E., Mäger, I., Ezzat, K., Sork, H., Copolovici, D. M., Viola, J. R., Zaghloul, E. M., Lundin, P., Moreno, P. M. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.10 · Cited by 129
“Lane numbers on the images on c–e represent: (1) naked plasmid, (2) CPP/plasmid complexes, (3–7) CPP/plasmid complexes treated with heparin sodium at the concentrations of 1.”
MethodBarriers to inhaled gene therapy of obstructive lung diseases: A review
Kim, N., Duncan, G. A., Hanes, J., & Suk, J. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.031 · Cited by 118
“Another limitation of retroviral vectors is their inability to infect non-dividing cells [121], which limits their use for inhaled gene therapy applications given the slow turnover rate of airway epithelium [7].”
Li, X., Yang, Y., Fan, Y., Feng, Q., Cui, F., & Watari, F. (2013) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.34801 · Cited by 127
Lomas, H., Du, J., Cantón, I., Madsen, J., Warren, N. J., Armes, S. P., Lewis, A. L., & Battaglia, G. (2010) · Macromolecular Bioscience · doi:10.1002/mabi.201000083 · Cited by 128
Temmerman, M. D., Dewitte, H., Vandenbroucke, R. E., Lucas, B., Libert, C., Demeester, J., Smedt, S. C. D., Lentacker, I., & Rejman, J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.024 · Cited by 127
Exosomes and their Application in Biomedical Field: Difficulties and Advantages
Rezaie, J., Ajezi, S., Avcı, Ç. B., Karimipour, M., Geranmayeh, M. H., Nourazarian, A., Sokullu, E., Rezabakhsh, A., & Rahbarghazi, R. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0582-7 · Cited by 128
“particular viruses have undergone special manipulation such as deletion of viral genes that lead to infection, toxicity, and other unnecessary aspects [13].”
BackgroundBiomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
Ultrasound-induced cavitation: applications in drug and gene delivery
Paliwal, S., & Mitragotri, S. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.6.713 · Cited by 125
“A number of viral and non-viral approaches have been proposed, but they suffer from limitations, including safety concerns for viral vectors and low expression for non-viral carriers [57,58].”
BackgroundRNA silencing: no mercy for viruses?
Lecellier, C., & Voinnet, O. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00128.x · Cited by 125
“larly encountered in the general design of gene therapy tools, notably, the choice of vector (either viral-based or synthetic) that ensure duration and tissue specificity of the curative effect (116).”
BackgroundAdvances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
“Almost always, virus-based gene delivery is accomplished by using replication-deficient viruses containing the gene of interest, but with the disease-causing sequences deleted from the viral genome.([2]) Both RNA and DNA viruses have been utilized.”
Micro-/nanoscale electroporation
Chang, L., Li, L., Shi, J., Sheng, Y., Lu, W., Gallego‐Perez, D., & Lee, L. J. (2016) · Lab on a Chip · doi:10.1039/c6lc00840b · Cited by 124
An Overview of Nanotechnologies for Drug Delivery to the Brain
Ayub, A., & Wettig, S. D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020224 · Cited by 126
Targa, F. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:3:337 · Cited by 124
“Distinct types of viruses have been engineered to become highly specific and efficient for gene delivery to particular cell types or tissues (2,90,92).”
BackgroundInfluentialNon-viral gene delivery systems for tissue repair and regeneration
Wu, P., Chen, H., Jin, R., Weng, T., Ho, J. K., You, C., Zhang, L., Wang, X., & Han, C. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1402-1 · Cited by 122
“But insertion mutation and other adverse effects have been observed during the post-transfection periods after viral gene delivery [11], resulting in the uncertainty and controversy about the application of VV for TRR.”
BackgroundKozielski, K., Ruiz‐Valls, A., Tzeng, S. Y., Guerrero‐Cazares, H., Rui, Y., Li, Y., Vaughan, H. J., Gionet‐Gonzales, M., Vantucci, C. E., Kim, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.020 · Cited by 122
Gene therapy for neurological disorders: challenges and recent advancements
Peña, S., Iyengar, R., Eshraghi, R. S., Bencie, N., Mittal, J., Aljohani, A., Mittal, R., & Eshraghi, A. A. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1630415 · Cited by 122
“The development of helper-dependent ADV (HD-ADV) removed all viral genes, thereby eliminating virulence [72].”
BackgroundKuroda, H., Kutner, R. H., Bazan, N. G., & Reiser, J. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.11.021 · Cited by 121
Hauff, P., Seemann, S., Reszka, R. C., Schultze‐Mosgau, M., Reinhardt, M., Buzasi, T., Plath, T., Rosewicz, S., & Schirner, M. (2005) · Radiology · doi:10.1148/radiol.2362040870 · Cited by 121
Antiangiogenic gene therapy of cancer: recent developments
Tandle, A., Blazer, D. G., & Libutti, S. K. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-22 · Cited by 113
Cell delivery therapeutics for musculoskeletal regeneration☆
Nöth, U., Rackwitz, L., Steinert, A. F., & Tuan, R. S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.004 · Cited by 119
Designing Nonviral Vectors for Efficient Gene Transfer and Long-Term Gene Expression
Jackson, D. A., Juranek, S., & Lipps, H. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.026 · Cited by 105
Jin, Y., Lee, J. S., Kim, J., Min, S., Wi, S., Yu, J. H., Chang, G.-E., Cho, A.-N., Choi, Y., Ahn, D.-H., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0260-8 · Cited by 111
Bartholomeusz, G. A., Cherukuri, P., Kingston, J., Cognet, L., Lemos, R., Leeuw, T. K., Gumbiner-Russo, L., Weisman, R. B., & Powis, G. (2009) · Nano Research · doi:10.1007/s12274-009-9026-7 · Cited by 119
“Whereas viral vectors can have the drawbacks of inducing immune responses, inflammation, and (potentially) oncogenic effects [43], the SWCNT delivery agent appears nontoxic to most cells.”
BackgroundProtein Delivery into the Cell Cytosol using Non-Viral Nanocarriers
Lee, Y.-W., Luther, D. C., Kretzmann, J. A., Burden, A., Jeon, T., Zhai, S., & Rotello, V. M. (2019) · Theranostics · doi:10.7150/thno.34412 · Cited by 119
“Viruses provide effective vectors for these nucleic acid-based deliveries, having evolved naturally to be capable of delivering their genetic cargo to infect the host cell and express new gene sequences [23].”
BackgroundZhang, D., Atochina‐Vasserman, E. N., Lu, J., Maurya, D. S., Xiao, Q., Liu, M., Adamson, J., Ona, N. A., Reagan, E. K., Ni, H., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00273 · Cited by 118
Kren, B. T., Unger, G. M., Sjeklocha, L. M., Trossen, A. A., Korman, V. L., Diethelm-Okita, B. M., Reding, M. T., & Steer, C. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci34332 · Cited by 119
“It has been a major focus of gene replacement strategies, using primarily virus-based vectors for in vivo gene delivery (1).”
BackgroundSuzuki, K., Mitsui, K., Aizawa, E., Hasegawa, K., Kawase, E., Yamagishi, T., Shimizu, Y., Suemori, H., Nakatsuji, N., & Mitani, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806976105 · Cited by 108
“Adenoviral vectors (AdVs) efficiently transduce a broad range of cell types and have been used extensively in preclinical and clinical studies of gene therapy (18, 19).”
BackgroundMyocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression
Turnbull, I. C., Eltoukhy, A. A., Fish, K. M., Nonnenmacher, M., Ishikawa, K., Chen, J., Hajjar, R. J., Anderson, D. G., & Costa, K. D. (2016) · Molecular Therapy · doi:10.1038/mt.2015.193 · Cited by 112
Guo, J., Bourré, L., Soden, D. M., O’Sullivan, G. C., & O’Driscoll, C. M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.03.003 · Cited by 117
“…R. Takahashi, C. Lu, et al., Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma, Nat Med 12 (2006), pp. 939-944 Thomas et al., 2003 C.E. Thomas, A. Ehrhardt, M.A. Kay, Progress and problems with the use of viral vectors for gene therapy, Nat Rev Genet 4…”
BackgroundNanoparticles for retinal gene therapy
Conley, S. M., & Naash, M. I. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.004 · Cited by 101
Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy
Venkatesha, S. H., Dudics, S., Acharya, B., & Moudgil, K. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010887 · Cited by 116
“It has shown that viral vectors may possess the risk of inducing an immune response, of vector spreading to other tissues, and of causing insertional mutagenesis, oncogenic transformations and lymphoproliferative disorders [82–84,98,99].”
BackgroundBiomedical investigation of CNT based coatings
Li, X., Liu, X., Huang, J., Fan, Y., & Cui, F. (2011) · Surface and Coatings Technology · doi:10.1016/j.surfcoat.2011.02.063 · Cited by 116
Surface Engineering for Cell-Based Therapies: Techniques for Manipulating Mammalian Cell Surfaces
Abbina, S., Siren, E. M. J., Moon, H., & Kizhakkedathu, J. N. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00514 · Cited by 116
Gene Therapy for Bone Regeneration
Luo, J., Sun, M., Kang, Q., Peng, Y., Jiang, W., Luu, H., Luo, Q., Park, J., Li, Y., & Haydon, R. (2005) · Current Gene Therapy · doi:10.2174/1566523053544218 · Cited by 101
“Five major types of viral vectors can be divided into two groups based on whether their genomes persist in a non-integrated form (i.e., adenovirus and herpes virus) or become integrated into host chromosomes (i.e., retrovirus, adeno-associated virus, and lentivirus) [Thomas et al., 2003].”
BackgroundInfluentialSchambach, A., Galla, M., Modlich, U., Will, E., Chandra, S., Reeves, L., Colbert, M. C., Williams, D. A., Kalle, C. V., & Baum, C. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.005 · Cited by 115
Lei, Y., & Segura, T. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.027 · Cited by 115
“Although viral delivery is generally more efficient than non-viral approaches, it has limitations due to its potential immunogenicity and insertion mutagenesis [10].”
Cell-type-specific genome editing with a microRNA-responsive CRISPR–Cas9 switch
Hirosawa, M., Fujita, Y., Parr, C. J. C., Hayashi, K., Kashida, S., Hotta, A., Woltjen, K., & Saito, H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx309 · Cited by 110
“For example, gene therapy using virus vectors may integrate the transgene into host genomic regions randomly, and induce oncogenesis in some cases (6).”
BackgroundLiu, Y., Zhao, G., Xu, C., Luo, Y., Lu, Z.-D., & Wang, J. (2018) · Biomaterials Science · doi:10.1039/c8bm00263k · Cited by 114
PepFect14 Peptide Vector for Efficient Gene Delivery in Cell Cultures
Veiman, K.-L., Mäger, I., Ezzat, K., Margus, H., Lehto, T., Langel, K., Kurrikoff, K., Arukuusk, P., Suhorutšenko, J., Padari, K., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3003557 · Cited by 114
Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles
Evers, M. J. W., Du, W., Yang, Q., Kooijmans, S. A. A., Vink, A., van Steenbergen, M., Vader, P., de Jager, S. C. A., Fuchs, S. A., Mastrobattista, E., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.027 · Cited by 113
Huang, H., Yu, H. C., Tang, G., Wang, Q., & Li, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.012 · Cited by 113
History of Polymeric Gene Delivery Systems
Zhang, P., & Wagner, E. (2017) · Topics in Current Chemistry · doi:10.1007/s41061-017-0112-0 · Cited by 113
Chang, J.-H., Tsai, P., Wang, K., Wei, Y.-T., Chiou, S., & Mou, C. (2018) · Scientific Reports · doi:10.1038/s41598-017-18324-8 · Cited by 113
Nucleic Acid–Based Functional Nanomaterials as Advanced Cancer Therapeutics
Yuan, Y., Gu, Z., Yao, C., Luo, D., & Yang, D. (2019) · Small · doi:10.1002/smll.201900172 · Cited by 113
Chen, Y., Huang, X.-C., Luo, Y.-L., Chang, Y.-C., Hsieh, Y., & Hsu, H. (2013) · Science and Technology of Advanced Materials · doi:10.1088/1468-6996/14/4/044407 · Cited by 113
“However, the severe concerns of viral-based nanocarriers, including oncogenic effects and immunogenicity, remain unsolved [156].”
BackgroundNelson, N., Port, J., & Pandey, M. (2020) · Journal of Nanotheranostics · doi:10.3390/jnt1010008 · Cited by 101
“While only limited success has been achieved in the past due to immunogenicity induced by the delivery vectors of biotherapeutics [164], modifications of SPIONs to include biocompatible coatings have prompted recent success.”
BackgroundRecent Advances in Microscale Electroporation
Choi, S., Khoo, H., & Hur, S. C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00677 · Cited by 112
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Raisin, S., Belamie, E., & Morille, M. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.017 · Cited by 111
Nanoparticle applications in ocular gene therapy
Cai, X., Conley, S. M., & Naash, M. I. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.012 · Cited by 111
Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model
Marti, G. P., Ferguson, M. W. J., Wang, J., Byrnes, C. K., Dieb, R., Qaiser, R. A., Bonde, P., Duncan, M., & Harmon, J. W. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302383 · Cited by 111
Small‐Molecule End‐Groups of Linear Polymer Determine Cell‐type Gene‐Delivery Efficacy
Sunshine, J. C., Green, J. J., Mahon, K. P., Yang, F., Eltoukhy, A. A., Nguyen, D. N., Langer, R., & Anderson, D. G. (2009) · Advanced Materials · doi:10.1002/adma.200901718 · Cited by 110
Gene Therapy for ALS—A Perspective
Cappella, M., Ciotti, C., Cohen-Tannoudji, M., & Biferi, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184388 · Cited by 98
“LV was considered the vector of choice for gene therapy due to its ability to transduce dividing and non-dividing cells (such as neurons), its ability to naturally penetrate an intact nuclear membrane [89] and its large cloning capacity (8–10 Kb) [85,90].”
BackgroundJang, J.-H., Koerber, J. T., Kim, J.-S., Asuri, P., Vazin, T., Bartel, M., Keung, A., Kwon, I., Park, K. I., & Schaffer, D. V. (2011) · Molecular Therapy · doi:10.1038/mt.2010.287 · Cited by 101
Ingato, D., Edson, J. A., Zakharian, M., & Kwon, Y. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b05377 · Cited by 106
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Li, X., Qi, J., Wang, J., Hu, W., Zhou, W., Wang, Y., & Li, T. (2024) · Theranostics · doi:10.7150/thno.84291 · Cited by 111
“However, undesired immune responses, toxicity, and vector size are the limiting obstacles to its further development [8].”
BackgroundClements, B. A., Incani, V., Kucharski, C., Lavasanifar, A., Ritchie, B. C., & Uludağ, H. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.07.023 · Cited by 109
Site-Specific Integration of Functional Transgenes into the Human Genome by Adeno/AAV Hybrid Vectors
Recchia, A., Perani, L., Sartori, D., Olgiati, C., & Mavilio, F. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.003 · Cited by 92
“Adenoviral (Ad) or adeno-associated viral (AAV) DNA vectors, on the other hand, do not normally integrate or do so sporadically and with unpredictable configurations [3].”
Zhang, R., Zheng, N., Song, Z., Yin, L., & Cheng, J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.097 · Cited by 109
“Viral vectors, although highly efficient, often suffer from severe safety concerns such as carcinogenicity, immunogenicity and insertional mutagenesis [5].”
BackgroundIn Vivo Delivery Systems for Therapeutic Genome Editing
Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., Xu, X., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050626 · Cited by 109
“However, they have been avoided because of multiple tragedies involving patient death in earlier clinical trials [36,37].”
BackgroundXu, Q., Zhang, Z., Zhao, L., Qin, Y., Cai, H., Geng, Z., Zhu, X., Zhang, W., Zhang, Y., Tan, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.033 · Cited by 102
A review of the tortuous path of nonviral gene delivery and recent progress
Sharma, D., Arora, S., Singh, J., & Layek, B. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.05.192 · Cited by 108
Therapeutic targeting in the silent era: advances in non-viral siRNA delivery
Guo, J., Fisher, K. A., Darcy, R., Cryan, J. F., & O’Driscoll, C. M. (2010) · Molecular BioSystems · doi:10.1039/c001050m · Cited by 108
“The recent case, in which a retroviral vector’s site of insertion into the genome appears to have activated a cancer-causing gene, has come further endorsed the search for efficient non-viral delivery technologies [12] .”
InfluentialCurrent status of non-viral gene therapy for CNS disorders
Jayant, R. D., Sosa, D., Kaushik, A., Atluri, V., Vashist, A., Tomitaka, A., & Nair, M. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1188802 · Cited by 91
Blundell, J. R., & Levy, S. F. (2014) · Genomics · doi:10.1016/j.ygeno.2014.09.005 · Cited by 107
Walisko, O., Schorn, A. J., Rolfs, F., Devaraj, A., Miskey, C., Izsvák, Z., & Ivics, Z. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300366 · Cited by 108
“Virus-based vectors are widely used in gene therapy applications, [2,3,4] because they allow efficient delivery of the therapeutic gene into a target cell population.”
BackgroundCui, L., Cohen, J. L., Chu, C. K., Wich, P. R., Kierstead, P. H., & Fréchet, J. M. J. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305552u · Cited by 91
Elsabahy, M., & Wooley, K. L. (2012) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.25955 · Cited by 105
Jin, Y., Seo, J., Lee, J. S., Shin, S., Park, H., Min, S., Cheong, E., Lee, T., & Cho, S. (2016) · Advanced Materials · doi:10.1002/adma.201601900 · Cited by 105
Sheehy, E. J., Kelly, D. J., & O’Brien, F. J. (2019) · Materials Today Bio · doi:10.1016/j.mtbio.2019.100009 · Cited by 106
“However, some safety concerns exist regarding the use of viral vectors in gene-activated scaffolds, which can be leveraged to deliver therapeutic genes to the site of interest [166].”
BackgroundPolymer beacons for luminescence and magnetic resonance imaging of DNA delivery
Bryson, J. M., Fichter, K. M., Chu, W., Lee, J. H., Li, J., Madsen, L. A., McLendon, P. M., & Reineke, T. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904860106 · Cited by 105
“Although much is known about the infection pathways, advantages, and troubles of viral vectors (6), researchers in the field of nonviral delivery are just beginning to understand the transfection mechanisms, benefits, and potential issues with the multitude of materials being developed as macromolecular drug carriers…”
BackgroundHost determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 97
“In the last three decades, recombinant virus vectors such as those derived from adenoviruses, retroviruses and lentiviruses, have emerged as highly efficient gene delivery vehicles, although safety issues are an ongoing concern [1,2].”
BackgroundInkjet printing of mammalian cells – Theory and applications
Kumar, P., Ebbens, S. J., & Zhao, X. (2021) · Bioprinting · doi:10.1016/j.bprint.2021.e00157 · Cited by 104
Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy
Yu, J., Zhou, B., Zhang, S., Yin, H., Sun, L., Pu, Y., Zhou, B., Sun, Y., Li, X., Fang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35580-z · Cited by 104
Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy
Gholami, A., Mohkam, M., Soleimanian, S., Sadraeian, M., & Lauto, A. (2024) · Microsystems & Nanoengineering · doi:10.1038/s41378-024-00743-z · Cited by 104
“Until now, the predominant means of delivering CRISPR/ Cas9 systems have chie fl y revolved around physical methodologies or viral vectors, thereby imposing constraints on their versatility and posing notable immunological hurdles 161,162 .”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.